 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery
|
|
|
|
Phase III
|
|
|
|
ECOG-E2805
E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
|
|
| |
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
|
|
|
|
Phase III
|
|
|
|
A6181109
NCT00375674
|
|
| |
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
|
|
|
Phase III
|
|
|
|
A6181114
NCT00428220
|
|
| |
Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
|
|
|
|
Phase III
|
|
|
|
3066K1-3311
NCT00631371
|
|
| |
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
|
|
|
|
Phase III
|
|
|
|
108844
COMPARZ, NCT00720941
|
|
| |
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
AECM-0501007709
NYWCCC-0501007709, NCI-6981, 6981, NCT00121251
|
|
| |
Bortezomib and Bevacizumab ("BB-Mib-Mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
|
|
|
|
Phase II, Phase I
|
|
|
|
4K-05-1
NCT00184015
|
|
| |
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
JHOC-J0570
JHOC-00001107, NCI-6884, 6884, NCT00324870
|
|
| |
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
NYWCCC-0511008257
6896, NCI-6896, NCT00324740
|
|
| |
Sorafenib and RAD001 Renal Cell Carcinoma
|
|
|
|
Phase II, Phase I
|
|
|
|
UCSF06523
NCT00384969
|
|
